These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33110015)

  • 41. Hepatocellular carcinoma downstaging in liver transplantation.
    Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
    Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient.
    Zhou K; Mehta N
    Clin Liver Dis; 2020 Nov; 24(4):665-679. PubMed ID: 33012452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
    Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
    Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
    Mazzaferro V; Citterio D; Bhoori S; Bongini M; Miceli R; De Carlis L; Colledan M; Salizzoni M; Romagnoli R; Antonelli B; Vivarelli M; Tisone G; Rossi M; Gruttadauria S; Di Sandro S; De Carlis R; Lucà MG; De Giorgio M; Mirabella S; Belli L; Fagiuoli S; Martini S; Iavarone M; Svegliati Baroni G; Angelico M; Ginanni Corradini S; Volpes R; Mariani L; Regalia E; Flores M; Droz Dit Busset M; Sposito C
    Lancet Oncol; 2020 Jul; 21(7):947-956. PubMed ID: 32615109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liver transplantation for hepatocellular carcinoma: results of a multicenter study with common priorization criteria.
    Santoyo J; Sanchez B; de la Mata M; Fernández-Aguilar JL; Lopez-Ciller P; Pascasio JM; Suarez MA; Gomez MA; Nogueras F; Muffak K; Cuende N; Alonso M
    Transplant Proc; 2009 Apr; 41(3):1009-11. PubMed ID: 19376412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Locoregional therapy of hepatocellular carcinoma.
    Habib A; Desai K; Hickey R; Thornburg B; Lewandowski R; Salem R
    Clin Liver Dis; 2015 May; 19(2):401-20. PubMed ID: 25921670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.
    Graziadei IW; Sandmueller H; Waldenberger P; Koenigsrainer A; Nachbaur K; Jaschke W; Margreiter R; Vogel W
    Liver Transpl; 2003 Jun; 9(6):557-63. PubMed ID: 12783395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?
    Cascales-Campos P; Martinez-Insfran LA; Ramirez P; Ferreras D; Gonzalez-Sanchez MR; Sanchez-Bueno F; Robles R; Pons JA; Capel A; Parrilla P
    Transplant Proc; 2018 Mar; 50(2):591-594. PubMed ID: 29579861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatocellular carcinoma: interventional bridging to liver transplantation.
    Lubienski A
    Transplantation; 2005 Sep; 80(1 Suppl):S113-9. PubMed ID: 16286887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
    Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
    Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
    Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience.
    Abdelfattah MR; Al-Sebayel M; Broering D; Alsuhaibani H
    Transplant Proc; 2015 Mar; 47(2):408-11. PubMed ID: 25769582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.
    Pelletier SJ; Fu S; Thyagarajan V; Romero-Marrero C; Batheja MJ; Punch JD; Magee JC; Lok AS; Fontana RJ; Marrero JA
    Liver Transpl; 2009 Aug; 15(8):859-68. PubMed ID: 19642139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
    Yao FY; Mehta N; Flemming J; Dodge J; Hameed B; Fix O; Hirose R; Fidelman N; Kerlan RK; Roberts JP
    Hepatology; 2015 Jun; 61(6):1968-77. PubMed ID: 25689978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bridging to liver transplantation in HCC patients.
    Kollmann D; Selzner N; Selzner M
    Langenbecks Arch Surg; 2017 Sep; 402(6):863-871. PubMed ID: 28755240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of Hepatocellular Carcinoma: Current Status and Future Directions.
    Au JS; Frenette CT
    Gut Liver; 2015 Jul; 9(4):437-48. PubMed ID: 26087860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
    Chapman WC; Majella Doyle MB; Stuart JE; Vachharajani N; Crippin JS; Anderson CD; Lowell JA; Shenoy S; Darcy MD; Brown DB
    Ann Surg; 2008 Oct; 248(4):617-25. PubMed ID: 18936575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.